Bispecific Versus CAR T-Cell Therapy for Myeloma and Bridging Therapy Needs for CAR-T

A roundtable discussion, moderated by Thomas Martin, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, focused on CAR T-cell therapy considerations in the treatment of multiple myeloma, including data on approved CAR-T options and a look at the pipeline. Dr. Martin was joined by a panel that included Sagar Lonial, MD, FACP; Peter Voorhees, MD; and Shambavi Richard, MD. In the next segment of the roundtable series, the panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.